ID: ALA262183

Max Phase: Preclinical

Molecular Formula: C37H40BrN3O6

Molecular Weight: 702.65

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccccc1N1CCN(CCC(Oc2ccc(C(=O)Nc3ccccc3OCCCC(=O)O)cc2)c2ccc(Br)cc2)CC1

Standard InChI:  InChI=1S/C37H40BrN3O6/c1-45-35-10-5-3-8-32(35)41-24-22-40(23-25-41)21-20-33(27-12-16-29(38)17-13-27)47-30-18-14-28(15-19-30)37(44)39-31-7-2-4-9-34(31)46-26-6-11-36(42)43/h2-5,7-10,12-19,33H,6,11,20-26H2,1H3,(H,39,44)(H,42,43)

Standard InChI Key:  JGSWBYKSTZJTPD-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 702.65

Molecular Weight (Monoisotopic): 701.2100

AlogP: 7.29

#Rotatable Bonds: 15

Polar Surface Area: 100.57

Molecular Species: ACID

HBA: 7

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.90

CX Basic pKa: 7.83

CX LogP: 4.24

CX LogD: 4.14

Aromatic Rings: 4

Heavy Atoms: 47

QED Weighted: 0.12

Np Likeness Score: -1.01

References

1. Yoshida K, Horikoshi Y, Eta M, Chikazawa J, Ogishima M, Fukuda Y, Sato H..  (1998)  Synthesis of benzanilide derivatives as dual acting agents with alpha 1-adrenoceptor antagonistic action and steroid 5-alpha reductase inhibitory activity.,  8  (21): [PMID:9873656] [10.1016/s0960-894x(98)00538-1]

Source

Source(1):

• Scientific Literature